FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
https://www.zacks.com/stock/news/2200645/fda-accepts-merck-s-mrk-bla-for-21-valent-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200645
Dec 20, 2023 - The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
0
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
https://www.zacks.com/stock/news/2200049/pfizer-pfe-stock-rises-on-fda-nod-for-expanded-use-of-padcev?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200049
Dec 19, 2023 - The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
0
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
https://www.zacks.com/stock/news/2200047/merck-mrk-gets-eu-nod-for-expanded-use-in-gastric-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200047
Dec 19, 2023 - Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
0
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
https://www.zacks.com/stock/news/2198897/moderna-mrna-soars-on-upbeat-data-from-cancer-therapy-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2198897
Dec 15, 2023 - Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
0
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
https://www.zacks.com/stock/news/2198513/pharma-stock-roundup-pfe-issues-weak-2024-view-azn-to-buy-icosavax-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198513
Dec 15, 2023 - Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
0
Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2198303/merck-mrk-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2198303
Dec 14, 2023 - Merck (MRK) concluded the recent trading session at $105.88, signifying a -1.15% move from its prior day's close.
0
Top Research Reports for Merck, Equinor & Illinois Tool Works
https://www.zacks.com/commentary/2196131/top-research-reports-for-merck-equinor-illinois-tool-works?cid=CS-ZC-FT-research_daily-2196131
Dec 11, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Equinor ASA (EQNR) and Illinois Tool Works Inc. (ITW).
0
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
https://www.zacks.com/stock/news/2195640/merck-s-mrk-keytruda-lynparza-combo-fails-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195640
Dec 08, 2023 - After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
0
Company News for Dec 8, 2023
https://www.zacks.com/stock/news/2195478/company-news-for-dec-8-2023?cid=CS-ZC-FT-corporate_summary-2195478
Dec 08, 2023 - Companies In The Article Are: CIEN,MRK,VRNT,OXM
0
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
https://www.zacks.com/stock/news/2193811/exelixis-exel-collaborates-with-arcus-for-kidney-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193811
Dec 05, 2023 - Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
0